Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion

Annals of Hematology

Volumn 91, Issue 2, 2012, Pages 309-310

  Cannella, Laura ^a   Latagliata, Roberto ^a   Breccia, Massimo ^a   Carmosino, Ida ^a   Loglisci, Giuseppina ^a   Volpicelli, Paola ^a   Ferretti, Antonietta ^a   Santopietro, Michelina ^a   Vozella, Federico ^a   Girmenia, Corrado ^a   Cuzzola, Mariella ^b   Oliva, Esther Natalie ^b   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; LENALIDOMIDE;

AGED; ANEMIA; ASTHENIA; CASE REPORT; CHROMOSOME DELETION 5; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL PAIN; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; MACROCYTIC ANEMIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; SKIN INFECTION; THROMBOCYTE COUNT; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANEMIA; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; HUMANS; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 84857363476     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1263-7     Document Type: Letter

References (8)

1. A List S Kurtin DJ Roe A Buresh D Mahadevan D Fuchs, et al. 2005 Efficacy of lenalidomide in myelodysplastic syndromes N Engl J Med 352 549 557 15703420 10.1056/NEJMoa041668 1:CAS:528:DC%2BD2MXhtFemsrc%3D (Pubitemid 40204668)
2. A List G Dewald J Bennett A Giagounidis A Raza E Feldman, et al. 2006 Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion N Engl J Med 355 1456 1465 17021321 10.1056/NEJMoa061292 1:CAS:528:DC%2BD28XhtVGgtrvO (Pubitemid 44511560)
3. V Kotla S Goel S Nischal C Heuck K Vivek B Das, et al. 2009 Mechanism of action of lenalidomide in hematological malignancies J Hematol Oncol 2 36 19674465 10.1186/1756-8722-2-36
4. BL Ebert J Pretz J Bosco CY Chang P Tamayo N Galili, et al. 2008 Identification of RPS14 as a 5q- syndrome gene by RNA interference screen Nature 451 335 339 18202658 10.1038/nature06494 1:CAS:528:DC%2BD1cXnt1Gjtw%3D%3D
5. AA Giagounidis S Haase M Heinsch G Gohring B Schlegelberger C Aul 2007 Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses Ann Hematol 86 133 137 17111142 10.1007/s00277-006-0217-y (Pubitemid 44964005)
6. D Durr RD Siciliano Y Hummel A O'Meara A Hirschi R Burkhard, et al. 2010 Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough? Ann Hematol 89 105 106 10.1007/s00277-009-0775-x
7. F Xu X Li C Chang Q He Z Zhang Q Zhang, et al. 2009 A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q) Leuk Res 33 e199 e202 19592091 10.1016/j.leukres.2009.06.009 1:CAS:528:DC%2BD1MXhtVegs7nP
8. Shaffer LG, Tommerup N (eds) (2005) ISCN 2005. An international system for human cytogenetic nomenclature (2005). Karger, Basel